Search results
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoBristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript April 25, 2024 Bristol...
Should You Pick Bristol Myers Squibb Stock At $45?
Forbes· 5 days agoDespite a Q1 beat, BMY stock corrected nearly 10% due to a lower than expected outlook for the full-year. After its recent fall, we think BMY stock has...
McAdam LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY)
ETF DAILY NEWS· 4 days agoMcAdam LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 6.2% during the fourth quarter, according to the company& ...
Bristol-Myers Squibb (NYSE:BMY) Given Average Rating of “Hold” by Analysts
ETF DAILY NEWS· 3 days agoOne research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and three have assigned a buy rating to the company. BMY has been the subject ...
Investors Purchase Large Volume of Bristol-Myers Squibb Put Options (NYSE:BMY)
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Wednesday. Investors bought 69,538 put options on the company ...
Bristol-Myers Squibb Expected to Earn Q2 2024 Earnings of $1.76 Per Share (NYSE:BMY)
ETF DAILY NEWS· 7 days agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Equities research analysts at Leerink Partnrs lowered their Q2 2024 EPS estimates for shares of
Judge tosses Medicare drug negotiation challenges from Bristol Myers Squibb, Johnson & Johnson
The Hill via Yahoo Finance· 5 days agoA federal judge on Monday threw out legal challenges to the Medicare negotiation program that had...
After 'reset,' Flagship startup lands $1.8B Bristol Myers Squibb deal - Boston Business Journal
The Business Journals· 7 days agoNissen's arrival coincided with Repertoire’s decision to scrap its two...-16 didn’t pan out. On...
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Morningstar· 4 days agoEditas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers ...
J&J, Bristol Myers lose challenges to US drug price negotiation program
Reuters· 6 days ago, opens new tab to a law requiring them to negotiate the prices of their blockbuster blood clot...